CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells

Journal of Immunology

Volumn 165, Issue 1, 2000, Pages 573-582

  Lee, Steven P ^a   Chan, Anthony T C ^b   Cheung, Siu Tim ^b,d   Thomas, Wendy A ^a   CroomCarter, Debbie ^a   Dawson, Chris W ^a   Tsai, Ching Hwa ^c   Leung, Sing Fai ^b   Johnson, Philip J ^b   Huang, Dolly P ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOLOGY; CELL CULTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0034235814     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.1.573     Document Type: Article

References (51)

1. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cylotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169.
2. Murray, R. J., M. G. Kurilla, J. M. Brooks, W. A. Thomas, M. Rowe, E. Kieff, and A. B. Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157.
3. + T-cells in acute infectious mononucleosis. Nat. Med. 2:906.
4. + T cells specific for EBV in healthy virus carriers. J. Immunol. 162:1827.
5. Shapiro, R. S., K. McClain, G. Frizzera, K. J. Gajl-Peczalska, J. H. Kersey, B. R. Blazar, D. C. Arthur, D. F. Patton, J. S. Greenberg, B. Burke, et al. 1988. Epstein-Barr virus-associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234.
6. Starzl, T. E., M. A. Nalesnik, K. A. Porter, M. Ho, S. Iwatsuki, B. P. Griffith, J. T. Rosenthal, T. R. Hakala, B. W. Shaw, R. L. Hardesty, et al. 1984. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin A-steroid therapy. Lancet 1:583.
7. Rooney, C. M., C. A. Smith, C. C. Ng, S. K. Loftin, J. W. Sixbey, Y. J. Gan, D. K. Srivastava, L. C. Bowman, R. A. Krance, M. K. Brenner, et al. 1998. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549.
8. Huang, D. P. 1991. Epidemiology and aetiology. In Nasopharyngeal Carcinoma, C. A. van Hasselt and A. G. Gibb, eds. Chinese University Press, Hong Kong, p. 23.
9. Qin, D. X., Y. H. Hu, J. H. Yan, G. Z. Xu, W. M. Cai, X. L. Wu, D. X. Cao, and X. Z. Gu. 1988. Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer 61:1117.
10. Lee, A. W. M., Y. F. Poon, W. Foo, S. C. K. Law, F. K. Cheung, D. K. K. Chan, S. Y. Tung, M. Thaw, and J. H. C. Ho. 1992. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 23:261.
11. Teo, P. M. L., W. H. Kwan, W. Y. Lee, S. F. Leung, and P. J. Johnson. 1996. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 77:2423.
12. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus. In Field Virology, 3rd Ed. B. N. Fields, D. M. Knipe, and P. M. Howley, eds. Lippincott-Raven, Philadelphia, p. 2397.
13. Brooks, L. A., A. L. Lear, L. S. Young, and A. B. Rickinson. 1993. Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J. Virol. 67:3182.
14. Levitskaya, J., A. Shapiro, A. Leonchiks, A. Ciechanover, and M. G. Masucci. 1997. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. USA 94:12616.
15. Young, L., C. Alfieri, K. Hennessy, H. Evans, C. O'Hara, K. C. Anderson, J. Ritz, R. S. Shapiro, A. Rickinson, E. Kieff, et al. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080.
16. Brooks, L., Q. Y. Yao, A. B. Rickinson, and L. S. Young. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:2689.
17. Busson, P., R. McCoy, R. Sadler, K. Gilligan, T. Tursz, and N. Raab-Traub. 1992. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J. Virol. 66:3257.
18. Gilligan, K., P. Rajadurai, J.-C. Lin, P. Busson, M. Abdel-Hamid, U. Prasad, T. Tursz, and N. Raab-Traub. 1991. Expression of the Epstein-Barr virus BumHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo. J. Virol. 65:6252.
19. Kienzle, N., T. B. Sculley, L. Poulsen, M. Buck, S. Cross, N. RaabTraub, and R. Khanna. 1998. Identification of a cytotoxic T-lymphocyte response to the novel BARFO protein of Epstein-Barr virus: a critical role for antigen expression. J. Virol. 72:6614.
20. Chan, S. H., T. S. Chew, E. H. Goh, M. J. Simons, and K. Shanmugaratnam. 1976. Impaired general cell-mediated immune functions in vivo and in vitro in patients with nasopharyngeal carcinoma. Int. J. Cancer 18:139.
21. Moss, D. J., S. H. Chan, S. R. Burrows, T. S. Chew, R. G. Kane, J. A. Staples, and N. Kunaratnam. 1983. Epstein-Barr virus T cell response in nasopharyngeal carcinoma patients. Int. J. Cancer 32:301.
22. Thomas, J. A., V. Iliescu, D. H. Crawford, R. Ellouz, M. Cammoun, and G. Dethe. 1984. Expression of HLA-DR antigens in nasopharyngeal carcinoma: an immunohistological analysis of the tumor cells and infiltrating lymphocytes. Int. J. Cancer 33:813.
23. Khanna, R., S. R. Burrows, V. Argaet, and D. J. Moss. 1994. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumor cell line. Int. Immunol. 6:639.
24. Teo, P. M. L., S. Y. Tsao, J. H. C. Ho, and P. Yu. 1991. A proposed modification of the Ho stage-classification for nasopharyngeal carcinoma. Radiother. Oncol. 21:11.
25. Baer, R., A. T. Bankier, M. D. Biggin, P. L. Deininger, P. J. Farrell, T. G. Gibson, G. Hatfull, G. S. Hudson, S. C. Satchwell, C. Seguin, et al. 1984. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310:207.
26. Busson, P., G. Ganem, P. Flores, F. Mugneret, B. Clausse, B. Caillou, K. Braham, H. Wakasugi, M. Lipinski, and T. Tursz. 1988. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int. J. Cancer 42:599.
27. Cheung, S. T., D. P. Huang, A. B. Y. Hui, K. W. Lo, C. W. Ko, Y. S. Tsang, N. Wong, B. M. Whitney, and J. C. K. Lee. 1999. Nasopharyngeal carcinoma cell line (c666-1) consistently harbouring Epstein-Barr virus. Int. J. Cancer 83:121.
28. Lee, S. P., R. J. Tierney, W. A. Thomas, J. M. Brooks, and A. B. Rickinson. 1997. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy J. Immunol. 158:3325.
29. Sadler, R. H., and N. RaabTraub. 1995. Structural analyses of the Epstein-Barr virus BamHI-A transcripts. J. Virol. 1132.
30. Hill, A. B., S. P. Lee, J. S. Haurum, N. Murray, Q. Y. Yao, M. Rowe, N. Signoret, A. B. Rickinson, and A. J. McMichael. 1995. Class I major histocompalibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid lines against which they were raised. J. Exp. Med. 181:2221.
31. + T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7:791.
32. Brooks, J. M., R. J. Murray, W. A. Thomas, M. G. Kurilla, and A. B. Rickinson. 1993. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J. Exp. Med. 178:879.
33. Burrows, S. R., J. Gardner, R. Khanna, T. Steward, D. J. Moss, S. Rodda, and A. Suhrbier. 1994. Five new cytotoxic T-cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J. Gen. Virol. 75:2489.
34. Gavioli, R., M. G. Kurilla, P. O. de Campos-Lima, L. E. Wallace, R. Dolcetti, R. J. Murray, A. B. Rickinson, and M. G. Masucci. 1993. Multiple HLA-A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J. Virol. 67:1572.
35. Lee, S. P., W. A. Thomas, R. J. Murray, F. Khanim, S. Kaur, L. S. Young, M. Rowe, M. Kurilla, and A. B. Rickinson. 1993. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J. Virol. 67:7428.
36. Lee, S. P., S. Morgan, J. Skinner, W. A. Thomas, S. R. Jones, J. Sutton, R. Khanna, H. C. Whittle, and A. B. Rickinson. 1995. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T-lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur. J. Immunol. 25:102.
37. Rickinson, A. B., and D. J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405.
38. Burrows, S. R., A. Suhrbier, R. Khanna, and D. J. Moss. 1992. Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing. Immunology 76:174.
39. Kelly, A., S. H. Powis, L. A. Kerr, I. Mockridge, T. Elliott, J. Bastin, B. Uchanskaziegler, A. Ziegler, J. Trowsdale, and A. Townsend. 1992. Assembly and function of the 2 ABC transporter proteins encoded in the human major histocompatibility complex. Nature 355:641.
40. Barnstable, C. J., W. F. Bodmer, G. Brown, G. Galfre, C. Milstein, A. F. Williams, and A. Zeigler. 1978. Production of monoclonal antibodies to group A erythrocytes. HLA and other human cell surface antigens: new tools for genetic analysis. Cell 14:9.
41. Chang, Y. W., and B. R. Hawkins. 1997. HLA class I and class II frequencies of a Hong Kong Chinese population based on bone marrow donor registry data. Hum. Immunol. 56:125.
42. Browning, M., and P. Krausa. 1996. Genetic diversity of HLA-A2: evolutionary and functional significance. Immunol. Today 17:165.
43. Khanna, R., P. Busson, S. R. Burrows, C. Raffoux, D. J. Moss, J. M. Nicholls, and L. Cooper. 1998. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res. 58:310.
44. Miller, G., and M. Lipman. 1973. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc. Natl. Acad. Sci. USA 70:190.
45. Zeng, Y. 1985. Seroepidemiological studies on nasopharyngeal carcinoma in China. Adv. Cancer Res. 44:121.
46. Lennette, E. T., G. Winberg, M. Yadav, G. Enblad, and G. Klein. 1995. Antibodies to LMP2A/2B in EBV-carrying malignancies. Ear. J. Immunol. 31A:1875.
47. Niedobitek, G., E. Kremmer, H. Herbst, L. Whitehead, C. W. Dawson, E. Niedobitek, C. vonOstau, N. Rooney, F. A. Grasser, and L. S. Young. 1997. Immunohistochemical detection of the Epstein-Barr virus-encoded latent membrane protein 2A in Hodgkin's disease and infectious mononucleosis. Blood 90: 1664.
48. Frisan, T., J. Sjoberg, R. Dolcetti, M. Boiocchi, V. Dere, A. Carbone, C. Brautbar, S. Battat, P. Biberfeld, M. Eckman, et al. 1995. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86:1493.
49. Malefyt, R. D., J. Haanen, H. Spits, M. G. Roncarolo, A. Tevelde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, and J. E. Devries. 1991. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J. Exp. Med. 174:915.
50. Yao, M., K. Ohshima, J. Suzumiya, T. Kume, T. Shiroshita, and M. Kikuchi. 1997. Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr virus-associated nasopharyngeal carcinoma. Int. J. Cancer 72:398.
51. de Campos-Lima, P.-O., V. Levitsky, J. Brooks, S. P. Lee, L. F. Hu, A. B. Rickinson, and M. G. Masucci. 1994. T cell responses and virus evolution: loss of HLA A11-restricted CTL epilopes in Epstein-Barr virus isolates from high A11-positive populations by selective mutation of anchor residues. J. Exp. Med. 179:1297.